Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A (301408) - Net Assets
Based on the latest financial reports, Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A (301408) has net assets worth CN¥2.24 Billion CNY (≈ $328.33 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥5.55 Billion ≈ $812.30 Million USD) and total liabilities (CN¥3.31 Billion ≈ $483.97 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Anhui Huaren Health Pharmaceutical Co. L tangible equity quality to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.24 Billion |
| % of Total Assets | 40.42% |
| Annual Growth Rate | 28.84% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 43.26 |
Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A - Net Assets Trend (2021–2025)
This chart illustrates how Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A's net assets have evolved over time, based on quarterly financial data. See Anhui Huaren Health Pharmaceutical Co. L liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A (2021–2025)
The table below shows the annual net assets of Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A from 2021 to 2025. For live valuation and market cap data, see Anhui Huaren Health Pharmaceutical Co. L market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.16 Billion ≈ $316.53 Million |
+4.98% |
| 2024-12-31 | CN¥2.06 Billion ≈ $301.51 Million |
+4.25% |
| 2023-12-31 | CN¥1.98 Billion ≈ $289.23 Million |
+108.71% |
| 2022-12-31 | CN¥947.01 Million ≈ $138.58 Million |
+20.63% |
| 2021-12-31 | CN¥785.05 Million ≈ $114.88 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 210.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥724.04 Million | 34.53% |
| Other Components | CN¥1.37 Billion | 65.47% |
| Total Equity | CN¥2.10 Billion | 100.00% |
Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A Competitors by Market Cap
The table below lists competitors of Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shanghai Runda Med Tech Co
SHG:603108
|
$915.17 Million |
|
Beijing New Space Technology Co Ltd
SHG:605178
|
$915.29 Million |
|
Shanghai Urban Architecture Design Co. Ltd.
SHE:300983
|
$915.36 Million |
|
Zhejiang Tiantie Industry Co Ltd
SHE:300587
|
$915.69 Million |
|
Shanghai Xinpeng Industry Co Ltd
SHE:002328
|
$914.77 Million |
|
Shenzhen Centralcon Investment Holding Co Ltd
SHE:000042
|
$914.49 Million |
|
Central Pacific Financial Corp
NYSE:CPF
|
$913.85 Million |
|
Ningxia Building Materials Group Co Ltd
SHG:600449
|
$913.15 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,005,289,910 to 2,096,977,527, a change of 91,687,617 (4.6%).
- Net income of 191,352,662 contributed positively to equity growth.
- Dividend payments of 56,745,145 reduced retained earnings.
- Other factors decreased equity by 42,919,900.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥191.35 Million | +9.13% |
| Dividends Paid | CN¥56.75 Million | -2.71% |
| Other Changes | CN¥-42.92 Million | -2.05% |
| Total Change | CN¥- | 4.57% |
Book Value vs Market Value Analysis
This analysis compares Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.98x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 6.77x to 2.98x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | CN¥2.31 | CN¥15.63 | x |
| 2022-12-31 | CN¥2.79 | CN¥15.63 | x |
| 2023-12-31 | CN¥4.86 | CN¥15.63 | x |
| 2024-12-31 | CN¥5.01 | CN¥15.63 | x |
| 2025-12-31 | CN¥5.24 | CN¥15.63 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 9.13%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.49%
- • Asset Turnover: 1.00x
- • Equity Multiplier: 2.62x
- Recent ROE (9.13%) is below the historical average (9.55%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 8.88% | 2.98% | 1.19x | 2.51x | CN¥-8.75 Million |
| 2022 | 16.97% | 4.93% | 1.27x | 2.72x | CN¥66.05 Million |
| 2023 | 5.90% | 3.02% | 0.82x | 2.37x | CN¥-79.69 Million |
| 2024 | 6.87% | 3.04% | 0.94x | 2.41x | CN¥-62.83 Million |
| 2025 | 9.13% | 3.49% | 1.00x | 2.62x | CN¥-18.35 Million |
Industry Comparison
This section compares Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A's net assets metrics with peer companies in the Pharmaceutical Retailers industry.
Industry Context
- Industry: Pharmaceutical Retailers
- Average net assets among peers: $3,180,038,052
- Average return on equity (ROE) among peers: 12.34%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A (301408) | CN¥2.24 Billion | 8.88% | 1.47x | $914.89 Million |
| Cachet Pharmaceutical Co Ltd (002462) | $5.92 Billion | 5.01% | 1.80x | $586.93 Million |
| Yunnan Hongxiang Yixintang (002727) | $810.77 Million | 22.52% | 0.88x | $941.76 Million |
| Luyan Pharma Co Ltd (002788) | $3.32 Billion | 8.45% | 3.03x | $637.88 Million |
| Ji Yao Holding Group Co Ltd (300108) | $58.56 Million | 22.82% | 0.31x | $20.47 Million |
| ShuYu Civilian Pharmacy Corp. Ltd. (301017) | $1.91 Billion | 6.00% | 1.61x | $804.83 Million |
| Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd (301126) | $977.24 Million | 8.97% | 1.06x | $285.54 Million |
| Shanghai No1 Pharmacy Co Ltd (600833) | $186.74 Million | 13.27% | 2.88x | $325.79 Million |
| Dashenlin Pharm Grp Co Ltd (603233) | $8.14 Billion | 11.24% | 2.25x | $2.76 Billion |
| Laobaixing Pharmacy (603883) | $7.29 Billion | 12.75% | 1.91x | $1.33 Billion |
About Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A
Anhui Huaren Health Pharmaceutical Co., Ltd. operates in the medical and healthcare industry. It offers products for oral and throat, nourishing, heat-clearing, respiratory system, and gynecology, as well as provides vitamins and minerals, and detoxifying products. In addition, it provides supplements, and nutrition and health products. Anhui Huaren Health Pharmaceutical Co., Ltd. was founded in … Read more